List of Excipients in Branded Drug CLOBETASOL PROPIONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	ANHYDROUS CITRIC ACID
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	CETYL ALCOHOL
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	CYCLOMETHICONE
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	ISOPROPYL MYRISTATE
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	LIGHT MINERAL OIL
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	PETROLATUM
Mylan Pharmaceuticals Inc	CLOBETASOL PROPIONATE	clobetasol propionate	0378-8055	PHENOXYETHANOL

Generic Drugs Containing CLOBETASOL PROPIONATE

Company	Ingredient	NDC	Excipient
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.	clobetasol propionate	0168-0162	PETROLATUM
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.	clobetasol propionate	0168-0162	PROPYLENE GLYCOL
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.	clobetasol propionate	0168-0162	SORBITAN SESQUIOLEATE
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	clobetasol propionate	0168-0269	CARBOMER HOMOPOLYMER TYPE B
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	clobetasol propionate	0168-0269	ISOPROPYL ALCOHOL
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	clobetasol propionate	0168-0269	SODIUM HYDROXIDE
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	clobetasol propionate	0168-0269	WATER

What are the Most Frequently-Used Excipients in CLOBETASOL PROPIONATE?

# Of NDCs	Excipient
30	ALCOHOL
37	ANHYDROUS CITRIC ACID
17	ANHYDROUS TRISODIUM CITRATE
1	BUTANE
1	CARBOMER 1342
3	CARBOMER 934
1	CARBOMER COPOLYMER TYPE A

Clobetasol Propionate Excipient Strategy and Commercial Opportunities

Last updated: February 27, 2026

What are the key excipient considerations for Clobetasol Propionate formulations?

Clobetasol Propionate (CP) is a superpotent topical corticosteroid used in treating inflammatory skin conditions. Formulation options include creams, ointments, gels, and solutions, each requiring specific excipients to optimize stability, bioavailability, and patient compliance.

Common excipients:

• Emollients (liquid paraffin, mineral oil)
• Emulsifiers (cetostearyl alcohol, polysorbates)
• Solvents (propylene glycol, ethanol)
• Stabilizers (antioxidants like butylated hydroxytoluene)
• Thickeners (carbomer, cetyl alcohol)
• Preservatives (methylparaben, phenoxyethanol)

The choice depends on the formulation type, desired release profile, and skin penetration characteristics.

How does excipient selection impact stability and efficacy?

Excipients influence compound stability, skin absorption, and shelf life. For example, ethanol acts as both solvent and preservative, enhancing drug solubility but may cause skin irritation. Carbomers increase viscosity, impacting patient acceptance. Antioxidants prevent degradation of CP, which is sensitive to oxidation.

Stability studies emphasize excipients that do not interact adversely with CP, preserving potency over 2-3 years. Proper selection reduces formulation flashpoints, improves manufacturability, and minimizes degradation risks.

What are strategic considerations for excipient sourcing and patents?

Sourcing high-purity excipients is critical for regulatory approval. Suppliers like BASF or Covestro offer certified materials. Patent landscapes around proprietary excipients can restrict formulations; thus, exploring off-patent, high-quality alternatives offers flexibility and cost advantages.

Brand differentiation can leverage patented excipients like certain novel emulsifiers or penetration enhancers. Patent filing around novel excipients or their combinations with CP permits market exclusivity for up to 20 years.

What commercial opportunities exist in excipient development for Clobetasol Propionate?

Opportunities include:

• Development of novel, bio-based excipients that enhance skin penetration and reduce irritation, aligning with clean-label trends.
• Formulation innovations that extend shelf life or reduce manufacturing costs via optimized excipient blends.
• Patent filing for unique combinations of excipients designed for specific formulations (e.g., foam, gel).

Contract manufacturing organizations (CMOs) seek specialized excipient blends to meet regulatory standards across different markets, representing a growth area.

What are regulatory considerations affecting excipient choices?

US FDA and EMA require excipients to be GRAS (Generally Recognized As Safe) or approved for topical use. For new excipients, toxicity, irritation, and sensitization data must be submitted. International harmonization emphasizes excipient transparency, including source and purity documentation, to streamline approval pipelines.

What market trends are influencing excipient strategies?

• Increased demand for preservative-free formulations drives innovation in preservative-free excipients like sorbitan esters or natural antimicrobials.
• Growing interest in plant-based excipients aligns with consumer preferences for natural products.
• Regulatory tightening emphasizes excipient safety profiles and limits on certain preservatives.

Key strategic approaches for excipient utilization in Clobetasol Propionate products

Approach	Description	Potential Benefit
Use of novel bio-based excipients	Incorporation of plant-derived ingredients	Meets clean-label demands; enhances market appeal
Optimization of excipient blends	Tailored combinations for stability and absorption	Improves therapeutic efficacy; reduces side effects
Patent-protected excipients	Securing patents for innovative excipient formulations	Provides market exclusivity
Regulatory-focused excipient selection	Compliance with global standards	Facilitates market entry across regions

Key Takeaways

• Excipient selection for Clobetasol Propionate formulations influences stability, efficacy, and patient adherence.
• Addressing regulatory requirements and sourcing constraints can create entry barriers; innovative or natural excipients provide differentiation.
• Commercial opportunities revolve around novel excipients, formulation optimization, and patent strategies.
• Trends favor preservative-free, natural, and stability-enhancing excipients, aligning with current market and regulatory demands.

FAQs

1. Which excipients are most common in Clobetasol Propionate topical formulations?
Emollients, emulsifiers, solvents, stabilizers, thickeners, and preservatives.

2. How do excipients affect the stability of Clobetasol Propionate?
They prevent oxidation, hydrolysis, and other degradation pathways, extending shelf life.

3. What are key regulatory hurdles for excipients in Clobetasol formulations?
Compliance with GRAS standards and safety data requirements for new excipients.

4. Can patenting excipient combinations provide competitive advantage?
Yes, patenting unique blends can secure market exclusivity and support higher pricing.

5. What are emerging trends in excipient development for topical corticosteroids?
Natural, preservative-free, and penetration-enhancing excipients aligned with consumer and regulatory preferences.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Topical and Transdermal Drug Products. Retrieved from https://www.fda.gov
[2] European Medicines Agency. (2020). Guideline on Excipients in the ICH Q3D-R1 Elemental Impurities.
[3] Smith, J., & Taylor, R. (2021). Advances in topical corticosteroid formulations. Journal of Pharmaceutical Sciences, 110(4), 1300–1314.